OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Review of Vaccines is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Relationship between attitudes toward the effectiveness of vaccine, concerns about adverse reactions, and proactively taking SARS-Cov-2 vaccine for family among medical workers in Taizhou, China	192
Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy	171
Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks?	92
Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response	91
Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant	86
Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States	76
Parental category B vaccine hesitancy and associated factors in China: an online cross-sectional survey	73
Indirect protection from rotavirus vaccines: a systematic review	65
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic	64
Safety of live attenuated influenza vaccine (LAIV) in children and adults with asthma: a systematic literature review and narrative synthesis	60
Response to letter to the editor on a systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children	59
Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumo	59
Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection	58
Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review	57
Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays	55
COVID-19 vaccination hesitancy in pregnant and breastfeeding women and strategies to increase vaccination compliance: a systematic review and meta-analysis	52
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era	50
Evaluation strategies for measuring pneumococcal conjugate vaccine impact in low-resource settings	49
Microarray patches: scratching the surface of vaccine delivery	48
The important lessons lurking in the history of meningococcal epidemiology	44
A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom	43
Effectiveness of maternal vaccination with quadrivalent inactivated influenza vaccine in pregnant women and their infants in 2019-2020	42
Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness	41
Personal and contextual determinants of COVID-19 vaccination intention: a vignette study	38
The protective effects of two varicella vaccination strategies: A Bayesian modeling study in two megacities in South China	38

Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis	36
Anti-COVID-19 vaccines and rare cases of cerebral venous sinus thrombosis with thrombocytopenia: what about the pragmatic benefit/risk evaluation for still unvaccinated young women	36
Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment	36
Who is more likely to hesitate to accept COVID-19 vaccine: a cross-sectional survey in China	35
Vaccines against leishmaniasis: using controlled human infection models to accelerate development	34
Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond	34
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion	33
Parental COVID-19 vaccine hesitancy: a cross-sectional survey in Italy	33
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above	33